Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1981 1
1983 2
1984 3
1985 1
1986 4
1987 3
1988 2
1989 4
1990 3
1991 3
1992 2
1993 3
1994 2
1995 2
1996 6
1997 4
1998 2
1999 8
2000 5
2001 7
2002 5
2003 8
2004 11
2005 7
2006 11
2007 15
2008 17
2009 16
2010 7
2011 12
2012 16
2013 20
2014 14
2015 24
2016 23
2017 34
2018 27
2019 28
2020 43
2021 49
2022 46
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

455 results
Results by year
Filters applied: . Clear all The following terms were ignored: %, %, %, % The following terms were not found in PubMed: 22Fiore, 5BAuthor
Page 1
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J. Reck M, et al. Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008. Epub 2019 Jun 11. Eur J Cancer. 2019. PMID: 31195357 Free article. Clinical Trial.
During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) …
During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI …
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, De La Fouchardiere C, Rivera F, Elez E, Diaz LA Jr, Yoshino T, Van Cutsem E, Yang P, Farooqui M, Le DT. Andre T, et al. Lancet Oncol. 2021 May;22(5):665-677. doi: 10.1016/S1470-2045(21)00064-4. Epub 2021 Apr 1. Lancet Oncol. 2021. PMID: 33812497 Clinical Trial.
HRQOL outcomes were mean change from baseline to prespecified week 18 in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire-Colorectal 29 (EORTC QLQ-CR29) scale and item scores, …
HRQOL outcomes were mean change from baseline to prespecified week 18 in European Organisation for Research and Treatment of Cancer Quality …
A randomized controlled trial of a walking training with simultaneous cognitive demand (dual-task) in chronic stroke.
Meester D, Al-Yahya E, Dennis A, Collett J, Wade DT, Ovington M, Liu F, Meaney A, Cockburn J, Johansen-Berg H, Dawes H. Meester D, et al. Eur J Neurol. 2019 Mar;26(3):435-441. doi: 10.1111/ene.13833. Epub 2018 Nov 25. Eur J Neurol. 2019. PMID: 30308699 Free PMC article. Clinical Trial.
Participants received a 10 week, bi-weekly, 30 min treadmill programme at an aerobic training intensity (55%-85% heart rate maximum), either with or without simultaneous cognitive demands. Outcome was measured at 0, 11 and 22 weeks. The primary assessment involved 2-min wa …
Participants received a 10 week, bi-weekly, 30 min treadmill programme at an aerobic training intensity (55%-85% heart rate maximum), either …
Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study.
Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, Takahashi H, Nakamura Y, Sotozono C, Oshika T, Morimoto T, Nishida K, Nishikawa N, Song YS, Tokutake T, Nishi Y, Shigeno Y, Kurihara T, Negishi K, Tsubota K, Ono M, Nakai T, Tan D, Tanaka S, Kinoshita S; ATOM-J. Study Group. Hieda O, et al. Jpn J Ophthalmol. 2021 May;65(3):315-325. doi: 10.1007/s10384-021-00822-y. Epub 2021 Feb 14. Jpn J Ophthalmol. 2021. PMID: 33586090 Clinical Trial.
The least squares mean change in SE and AL from baseline were, respectively, -1.26 D (95% confidence interval [CI]: -1.35, -1.17) and 0.63 mm (0.59, 0.67) for atropine and -1.48 D (- 1.57, -1.39) and 0.77 mm (0.73, 0.81) for placebo. Inter-group differences were 0.22 D (95 …
The least squares mean change in SE and AL from baseline were, respectively, -1.26 D (95% confidence interval [CI]: -1.35, -1.17) and 0.63 m …
Lanthanide Photocatalysis.
Qiao Y, Schelter EJ. Qiao Y, et al. Acc Chem Res. 2018 Nov 20;51(11):2926-2936. doi: 10.1021/acs.accounts.8b00336. Epub 2018 Oct 18. Acc Chem Res. 2018. PMID: 30335356
Among the lanthanides, we have focused on cerium because of the doublet to doublet 4f 5d excitation and emission, which affords good conservation of energy without losses through spin-state changes, as well as a large natural abundance of that element. ...This complex is a …
Among the lanthanides, we have focused on cerium because of the doublet to doublet 4f 5d excitation and emission, which affords good …
Complications and outcome after rib fracture fixation: A systematic review.
Peek J, Beks RB, Hietbrink F, Heng M, De Jong MB, Beeres FJP, Leenen LPH, Groenwold RHH, Houwert RM. Peek J, et al. J Trauma Acute Care Surg. 2020 Aug;89(2):411-418. doi: 10.1097/TA.0000000000002716. J Trauma Acute Care Surg. 2020. PMID: 32282759
The most frequently used questionnaire to assess patient quality of life was the EuroQol-5D (EQ-5D) (n = 4). Four studies reporting on the EQ-5D had a weighted mean EQ-5D index of 0.80 indicating good quality of life after rib fracture fixation. ...
The most frequently used questionnaire to assess patient quality of life was the EuroQol-5D (EQ-5D) (n = 4). Four studies repo …
Peripheral refraction and spherical aberration profiles with single vision, bifocal and multifocal soft contact lenses.
Fedtke C, Ehrmann K, Bakaraju RC. Fedtke C, et al. J Optom. 2020 Jan-Mar;13(1):15-28. doi: 10.1016/j.optom.2018.11.002. Epub 2019 Feb 13. J Optom. 2020. PMID: 30772211 Free PMC article. Clinical Trial.
PURPOSE: To compare the peripheral refraction and spherical aberration profiles along three visual field meridians of 16 commercial single vision (SV), bifocal (BF) and multifocal (MF) test contact lenses with a single vision control. METHOD: Forty-four participants [24.22
PURPOSE: To compare the peripheral refraction and spherical aberration profiles along three visual field meridians of 16 commercial single v …
Visual and Patient-Reported Outcomes of a Diffractive Trifocal Intraocular Lens Compared with Those of a Monofocal Intraocular Lens.
Modi S, Lehmann R, Maxwell A, Solomon K, Cionni R, Thompson V, Horn J, Caplan M, Fisher B, Hu JG, Yeu E. Modi S, et al. Ophthalmology. 2021 Feb;128(2):197-207. doi: 10.1016/j.ophtha.2020.07.015. Epub 2020 Sep 28. Ophthalmology. 2021. PMID: 33004211 Free article. Clinical Trial.
DESIGN: Food and Drug Administration-approved, prospective, multicenter, nonrandomized, parallel-group, assessor-masked, confirmatory trial. PARTICIPANTS: Patients enrolled were 22 years of age or older with a diagnosis of bilateral cataract with planned removal by phacoem …
DESIGN: Food and Drug Administration-approved, prospective, multicenter, nonrandomized, parallel-group, assessor-masked, confirmatory trial. …
Multifocal Femto-PresbyLASIK in Pseudophakic Eyes.
Pajic B, Massa H, Baenninger PB, Eskina E, Pajic-Eggspuehler B, Resan M, Cvejic Z. Pajic B, et al. J Clin Med. 2021 May 25;10(11):2282. doi: 10.3390/jcm10112282. J Clin Med. 2021. PMID: 34070242 Free PMC article.

RESULTS: 6 months after surgery a refraction of -0.11 0.13 D (p = 0.001), an uncorrected distance visual acuity of 0.05 1.0 logMAR (p < 0.001) and an uncorrected near visual acuity of 0.15 0.89 logMAR (p = 0.001) were achieved in the dominant eye. For the non-dominant eye, the

RESULTS: 6 months after surgery a refraction of -0.11 0.13 D (p = 0.001), an uncorrected distance visual acuity of 0.05 1.0 logMAR (p < 0

Five-Year Outcomes of a Randomized Trial of Treatments for Varicose Veins.
Brittenden J, Cooper D, Dimitrova M, Scotland G, Cotton SC, Elders A, MacLennan G, Ramsay CR, Norrie J, Burr JM, Campbell B, Bachoo P, Chetter I, Gough M, Earnshaw J, Lees T, Scott J, Baker SA, Tassie E, Francis J, Campbell MK. Brittenden J, et al. N Engl J Med. 2019 Sep 5;381(10):912-922. doi: 10.1056/NEJMoa1805186. N Engl J Med. 2019. PMID: 31483962 Free article. Clinical Trial.
Primary outcomes at 5 years were disease-specific quality of life and generic quality of life, as well as cost-effectiveness based on models of expected costs and quality-adjusted life-years (QALYs) gained that used data on participants' treatment costs and scores on the EuroQol …
Primary outcomes at 5 years were disease-specific quality of life and generic quality of life, as well as cost-effectiveness based on models …
455 results